228 Chapter 10 32. Chavez MA, Munigala S, Burnham CD, Yarbrough ML, Warren DK. The impact of implementing the virtuo blood culture system on the characteristics and management of patients with Staphylococcus aureus bacteremia. J Clin Microbiol. 2022;60(4):e0226121. 33. Chen PY, Chuang YC, Wang JT, Chang SC. Impact of prior healthcare-associated exposure on clinical and molecular characterization of methicillin-susceptible Staphylococcus aureus bacteremia: results from a retrospective cohort study. Medicine (Baltimore). 2015;94(5):e474. 34. Chen PY, Chuang YC, Wang JT, Sheng WH, Chen YC, Chang SC. Sequence type 8 as an emerging clone of methicillin-resistant Staphylococcus aureus causing bloodstream infections in Taiwan. Emerg Microbes Infect. 2021;10(1):1908-1918. 35. Chen SY, Wang JT, Chen TH, et al. Impact of traditional hospital strain of methicillinresistant Staphylococcus aureus (MRSA) and community strain of MRSA on mortality in patients with community-onset S aureus bacteremia. Medicine (Baltimore). 2010;89(5):285-294. 36. Chihara S, et al. Staphylococcus aureus bacteriuria as a prognosticator for outcome of Staphylococcus aureus bacteremia: A case-control study. BMC Infect Dis. 2009;10:225. 37. Chung H, Kim E, Yang E, et al. C-reactive protein predicts persistent bacteremia caused by community- acquired methicillin-resistant Staphylococcus aureus strain. Eur J Clin Microbiol Infect Dis. 2021;40(12): 2497-2504. 38. Cobussen M, van Tiel FH, Oude Lashof AML. Management of S. aureus bacteraemia in the Netherlands; infectious diseases consultation improves outcome. Neth J Med. 2018;76(7):322-329. 39. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol. 2005;26(2):166-174. 40. Eells SJ, McKinnell JA, Wang AA, et al. A comparison of clinical outcomes between healthcare-associated infections due to community-associated methicillin-resistant Staphylococcus aureus strains and healthcare- associated methicillin-resistant S. aureus strains. Epidemiol Infect. 2013;141(10):2140-2148. 41. Gasch O, Camoez M, Dominguez MA, et al; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013;19(11):1049-1057. 42. Greenberg JA, David MZ, Hall JB, Kress JP. Immune dysfunction prior to Staphylococcus aureus bacteremia is a determinant of long-term mortality. PLoS One. 2014;9(2):e88197. 43. Guillamet MCV, Vazquez R, Deaton B, Shroba J, Vazquez L, Mercier RC. Host-pathogentreatment triad: host factors matter most in methicillin-resistant Staphylococcus aureus bacteremia outcomes. Antimicrob Agents Chemother. 2018;62(2):e01902-17. 44. Hagstrand Aldman M, Kavyani R, Kahn F, Påhlman LI. Treatment outcome with penicillin G or cloxacillin in penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective cohort study. Int J Antimicrob Agents. 2022;59(4):106567. 45. Hall RG II, Giuliano CA, Haase KK, et al. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Infect Dis. 2012;12:104. 46. Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E. Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2012;56 (10):5164-5170.
RkJQdWJsaXNoZXIy MTk4NDMw